Hsiao D. Lieu - Mar 2, 2023 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role: SVP, Chief Medical Officer
Signature: /s/ Valerie Pierce, Attorney-in-fact
Stock symbol: NGM
Transactions as of: Mar 2, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/6/2023, 04:08 PM
Previous filing: Nov 8, 2022
Next filing: Nov 8, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NGM	Common Stock	Award	$0	+53K	+2034.55%	$0.00	55.6K	Mar 2, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NGM	Stock Option (Right to Buy)	Award	$0	+159K		$0.00	159K	Mar 2, 2023	Common Stock	159K	$4.36	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
F2	Includes 1,352 shares acquired under the Issuer's Employee Stock Purchase Plan (the "ESPP") on November 15, 2021, 1,252 ESPP shares acquired on May 13, 2022 and 1 ESPP share acquired on November 15, 2022.
F3	The shares subject to the stock option vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.